ClinicalTrials.gg

Program

BRL-301

A development code.

Its studies are mostly in Lupus Erythematosus, Systemic · Lymphoma, B-Cell, led by BRL Medicine.

Furthest: no phase, since Apr 19, 20233 company-led studies, 3 open or runningNext primary completion: Aug 15, 2027

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BRL Medicine33 open or runningno phasesince Apr 19, 2023Apr 19, 2023Aug 15, 2027NCT07248163

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 19, 2023First study: no phase study in Lupus Erythematosus, SystemicFirst studyNCT05859997 · 15 planned · China
  2. Aug 4, 2023No phase study in Lupus Erythematosus, SystemicNCT05988216 · 12 planned · China
  3. Nov 18, 2025No phase study in Non-hodgkin Lymphoma,B CellNCT07248163 · 6 planned · China

Ahead

  1. Aug 15, 2027Primary completion: no phase study in Non-hodgkin Lymphoma,B CellNCT07248163

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07248163Non-hodgkin Lymphoma,B Cell · China–RecruitingAug 15, 20276
NCT05988216Lupus Erythematosus, Systemic · China–RecruitingDec 202412
NCT05859997Lupus Erythematosus, Systemic · China–By invitationMay 27, 202415

How it is read

Names in the registry

  • “BRL-301”, 3 entries

Codes read as this program: BRL301.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.